LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that CUBICIN® (daptomycin for injection) received approvals in July for S. aureus bacteremia, including right-sided infective endocarditis (SAB/RIE), in both South Korea and Taiwan. The recent approval in South Korea includes both complicated skin and skin structure infections (cSSSI) and SAB/RIE. CUBICIN was previously approved in Taiwan (in November of 2006) for cSSSI caused by Gram positive bacteria. The approvals were received by Kuhnil Pharmaceutical Corp. (CUBICIN marketing partner for South Korea) and TTY BioPharm Company, Ltd. (CUBICIN marketing partner for Taiwan.)
